AT-13387

• CAT Number: I005444
• CAS Number: 912999-49-6
• Molecular Formula: C₂₄H₃₁N₃O₃
• Molecular Weight: 409.5
• Purity: ≥95%
• Target: HSP
• Solubility: DMSO: ≥ 33 mg/mL
• Storage: 3 years -20C powder
• IC50: 18 nM
• InChI: InChI=1S/C24H31N3O3/c1-16(2)20-11-21(23(29)12-22(20)28)24(30)27-14-18-5-4-17(10-19(18)15-27)13-26-8-6-25(3)7-9-26/h4-5,10-12,16,28-29H,6-9,13-15H2,1-3H3
• InChIKey: IFRGXKKQHBVPCQ-UHFFFAOYSA-N
• SMILES: CC(C)C1=C(C=C(C(=C1)C(=O)N2CC3=C(C2)C=C(C=C3)CN4CCN(CC4)C)O)O

AT-13387 (CAT: I005444) is a selective and potent inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a chaperone protein that plays a crucial role in the folding, stabilization, and function of various client proteins involved in cell signaling and survival. By inhibiting Hsp90, AT-13387 disrupts the proper folding and stability of these client proteins, leading to their degradation and inhibition of their signaling pathways. This inhibition can potentially have anti-cancer effects by targeting multiple oncogenic pathways that depend on Hsp90 for proper functioning. AT-13387 has shown promise in preclinical studies and is being investigated as a potential therapeutic agent for various types of cancer.

Reference

[1]. Woodhead AJ, Angove H, Carr MG et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem. 2010 Aug 26;53(16):5956-69. 


[2]. Graham B, Curry J, Smyth T et al. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci. 2012 Mar;103(3):522-7. 


[3]. Smyth T, Van Looy T, Curry JE et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther. 2012 Aug;11(8):1799-808. 


[4]. Kang MH, Reynolds CP, Houghton PJ et al. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Jul 15;59(1):185-8. 


[5]. Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors 


[6]. Active Clinical Trials with AT13387